Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mørk C, Sigurgeirsson B
Department of Dermatology, Aarhus University Hospital, Denmark.
Acta Derm Venereol. 2001 May;81(2):116-21. doi: 10.1080/00015550152384254.
The data from a questionnaire-based study of 5,739 members of the psoriasis associations of Denmark, Finland, Iceland, Norway, Sweden and the Faeroe Islands showed that the two most commonly used active agents were topical steroids (89.7% total use and 49.4% present use) and calcipotriol (73.1% total use and 35.8% present use), with only small variations between the countries. Marked differences between the countries were, however, found within all other types of psoriasis therapy, including the so-called alternative treatments. Significant priorities varied between the different countries. The use of dithranol in Finland was almost twice the average. While 14.2% of Danish members had received grenz-rays within the last week only 0.1% of the Finns had been given the same treatment. Psoralen plus ultraviolet A (PUVA) was being used by 13.1% of the Finnish psoriatics compared with 3.8% of Danes, while PUVA was almost non-existent on the Faeroe Islands. The use of non-PUVA phototherapy was highest in Norway and Sweden. Almost 10% of the Danes were presently on methotrexate, which was used far more than etretinate/acitretin or cyclosporine. In contrast, Finnish patients more often received etretinate than other systemic agents, and in Iceland there was a higher present use of cyclosporine than of etretinate. The popularity of alternative therapies was highest in Iceland, where 26.6% had taken such medication during the last week. The results of the study suggest that different treatment patterns should be taken into consideration when discussing the prognosis of psoriasis in different countries.
一项针对丹麦、芬兰、冰岛、挪威、瑞典以及法罗群岛银屑病协会5739名成员的问卷调查研究数据显示，两种最常用的活性剂为外用类固醇（总使用率89.7%，当前使用率49.4%）和卡泊三醇（总使用率73.1%，当前使用率35.8%），各国之间仅有细微差异。然而，在所有其他类型的银屑病治疗方法中，包括所谓的替代疗法，各国之间存在显著差异。不同国家的显著优先事项各不相同。芬兰地蒽酚的使用量几乎是平均水平的两倍。虽然14.2%的丹麦成员在过去一周内接受了境界线放疗，但只有0.1%的芬兰人接受了同样的治疗。13.1%的芬兰银屑病患者正在使用补骨脂素加紫外线A（PUVA）疗法，而丹麦的这一比例为3.8%，而法罗群岛几乎不存在PUVA疗法。挪威和瑞典非PUVA光疗的使用率最高。近10%的丹麦人目前正在使用甲氨蝶呤，其使用频率远高于依曲替酯/阿维A或环孢素。相比之下，芬兰患者比其他全身用药更常接受依曲替酯治疗，而冰岛目前环孢素的使用量高于依曲替酯。替代疗法在冰岛最受欢迎，上周有26.6%的人服用了此类药物。研究结果表明，在讨论不同国家银屑病的预后时，应考虑不同的治疗模式。
